HIV : New Agents, New Strategies

Slides:

Advertisements

Similar presentations

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER CROI 2015: Treatment and Cure Highlights Shireesha Dhanireddy Robert Harrington March 17, 2014 No financial.

Advertisements

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT-1 and HIV Coinfection NIAID ERADICATE Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

C-EDGE co-infection study: grazoprevir/ elbasvir in HIV coinfection GZR/EBR 100/50 mg qd N = 218  Design W12 W24 C-EDGE co-infection Rockstroh JK. Lancet.

Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.

NIAID ERADICATE Open-label W12 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve HIV infection on stable ART ≥ 8 weeks and HIV RNA < 50 c/ml.

Joel E. Gallant, MD, MPH Medical Director, Specialty Services Southwest CARE Center Santa Fe, New Mexico State-of-the-ART in Antiretroviral Management.

Sulkowski M. Lancet 2015;385: C-WORTHY  Design Randomisation* Open-label > 18 years HCV genotype 1, treatment naïve HCV RNA ≥ 10,000 IU/ml No cirrhosis.

Roth D. Lancet 2015; Oct 6; 386: C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR.

Switch to ATV/r monotherapy  ATARITMO  Swedish Study  ACTG A5201  OREY  MODAt Study.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

ID Week Review 2015 Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO October 2015.

به نام خداوند بخشنده مهربان. Treatment of HIV/HCV & HIV/HBV coinfection Dr. Davoudi Infectious diseases specialist Antimicrobial research center Mazandaran.

Phase 3 Treatment Experienced

Phase 3 Treatment-Naïve and Treatment-Experienced

Novel Antiretroviral Studies and Strategies

Sofosbuvir-Velpatasvir-Voxilaprevir in GT 3 and Cirrhosis POLARIS-3

ARV-trial.com Switch to TDF/FTC/EFV AI Study 1.

Phase 3 Treatment-Naïve and Treatment-Experienced

Sofosbuvir-Velpatasvir (Epclusa)

Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design

Interactive Workshop.

Switch to RPV-TDF-FTC from Ritonavir-boosted PI Regimen SPIRIT STUDY

Phase 3 Treatment-Naïve and Treatment-Experienced

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5

Sofosbuvir plus Peg-Interferon and Ribavirin in Treatment Experienced Patients with Hepatitis C Virus and HIV Co-Infection Mehri Nikbin, MD Infectious.

Phase 2 Treatment Naïve HIV Coinfection

Switching the NRTI Backbone to Tenofovir DF-Emtricitabine TOTEM

Phase 2 Treatment Naïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIAID SYNERGY: Genotype.

Case 53-year-old Black Man

Phase 2 Treatment Naïve Injection Drug Use

Advances in HIV Care.

The HCV Revolution: Are You and Your Practice Ready?

HIV Management: An Update on the Latest EACS Guidelines

Treating HIV Infection:

Phase 3 Treatment Naïve HIV Coinfection

Translating Emerging HIV Data Into Clinical Practice

Program Overview. Why, When, and How to Switch ART in Patients With HIV Who Have Achieved Viral Suppression.

Is it Time for a Paradigm Change in HIV Management?

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

New Agents, New Regimens, New Strategies

Care of the Treatment-naive Patient With HCV/HIV Coinfection

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

ION-3 Study: LDV/SOF + RBV for naïve genotype 1

Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3

ARV-trial.com TURQUOISE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for HCV in HIV co-infected patients Randomisation 1 : 1 Open-label.

Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection

Update From Seattle 2017.

Advances in the Treatment of HCV Genotype 3 and HIV/HCV Coinfection

Switch to LPV/r monotherapy

A Guideline-Based Approach to HCV Care

HIV Update 2018: A Front Row Seat

Phase 2 Treatment Naïve Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve HCV Genotype 1 or 3 C-SWIFT Poordad F, et al. EASL 2015; Abstract O006.

Switch to DRV/r monotherapy

Switch to LPV/r monotherapy

Comparison of NRTI combinations

What Does the Future Hold and What Will It Mean for Patients?

Switch to LPV/r monotherapy

Comparison of PI vs PI ATV vs ATV/r BMS 089

ARV-trial.com Switch to TDF/FTC/EFV AI Study 1.

Switch to ATV/r monotherapy

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Switch to LPV/r monotherapy

ARV-trial.com Switch to DTG/ABC/3TC STRIIVING NEAT

Phase 3 Treatment-Naïve and Treatment-Experienced

Sequencing cohorts Open-label Design W8 W12 ≥ 18 years

Presentation transcript:

HIV 2015-2016: New Agents, New Strategies

Learning Objectives

EARLY VS DEFERRED ART The Case is Made

Should Early-Stage Asymptomatic HIV Patients Receive ART Should Early-Stage Asymptomatic HIV Patients Receive ART? The INSIGHT START Study

The CD4+ Cell Count As a Measure of Immune Deficiency in HIV+ Patients How Good Is It?

Immediate vs Deferred ART and Isoniazid Preventive Therapy TEMPRANO Studya

Global Agreement on EARLY ART Initiation

INSTIs vs Boosted PIs ACTG 5257 Study

The Triumph of INSTIs Over Boosted PIs ACTG 5257 Study

INSTI vs Boosted PI SINGLE Study (N=833)

Dolutegravir Superior to Boosted Darunavir FLAMINGO Study (N=484)

INSTIs vs Boosted PIs in Treatment-Naïve Patients Summary of Clinical Evidence

Interesting But… Limitations of PADDLE

New Formulation of Tenofovir TAF

TAF Replaces TDF in Fixed-Dose Pill

Switching Virologically-Suppressed Patients From TDF- to TAF-Based Regimen Improved Virologic Outcomes at 48 Wk (N=1433)

Significant Improvement in BMD and Renal Function With Switch to TAF

Switching From TDF to TAF Improves Renal Function at 48 Wk in Patients With Renal Impairment

Fixed-Dose Tablet: DTG/ABC/3TC STRIIVING Study

Virologic Outcomes Maintained in Patients Switched to DTG/ABC/3TC STRIIVING Study

Possible Reasons for Discontinuations in STRIIVING Study

Dolutegravir Monotherapy Switch Study Suggests Benefit for Select Patients

Dolutegravir Monotherapy Proceed With Caution

EFFICACY OF ART IN HIV-INFECTED WOMEN

First All-Women Study of ART Efficacy WAVES Study

WAVES 48-Week Data

Why Did Results Differ From a Similar Study of Mostly Mena?

Why Is It Difficult to Recruit Women Into Clinical Trials?

Daclatasvir/Sofosbuvir for 8 vs 12 Wk to Treat HCV in HIV/HCV-Coinfected Patients ALLY-2 Study

Efficacy of Treating HCV With Ledipasvir/ Sofosbuvir for 12 Wk in HIV/HCV-Coinfected Patients ION-4 Study

New Combination of Sofosbuvir/ Velpatasvir Achieves High HCV SVR Rates Across HCV Genotypes ASTRAL-1 Study

Grazoprevir/Elbasvir: High HCV Cure Rates in HIV/HCV-Coinfected Patients C-EDGE CO-INFECTION

Treatment of HIV/HCV Coinfection Looking Forward

LONG-ACTING FORMULATIONS

Switch To a Long-Acting Nanoparticle Emulsion Formulation of Cabotegravir + Rilpivirine: 32-Wk Results LATTE-2 Studya,b

Potential Benefits of Long-Acting Injectable Agents

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)